Abstract: Disclosed herein are molecules and pharmaceutical compositions that induce an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion. Also described herein include methods for treating a disease or disorder that comprises a molecule or a pharmaceutical composition that induces an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion.

Abstract: Disclosed herein are molecules and pharmaceutical compositions that induce an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion. Also described herein include methods for treating a disease or disorder that comprises a molecule or a pharmaceutical composition that induces an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion.

Abstract: Disclosed herein are molecules and pharmaceutical compositions that induce an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion. Also described herein include methods for treating a disease or disorder that comprises a molecule or a pharmaceutical composition that induces an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion.

Abstract: Disclosed herein are molecules and pharmaceutical compositions that induce an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion. Also described herein include methods for treating a disease or disorder that comprises a molecule or a pharmaceutical composition that induces an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion.

Abstract: Disclosed herein are molecules and pharmaceutical compositions that induce an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion. Also described herein include methods for treating a disease or disorder that comprises a molecule or a pharmaceutical composition that induces an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion.

Abstract: Disclosed herein are molecules and pharmaceutical compositions that induce an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion. Also described herein include methods for treating a disease or disorder that comprises a molecule or a pharmaceutical composition that induces an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion.

Abstract: Disclosed herein are molecules and pharmaceutical compositions that induce an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion. Also described herein include methods for treating a disease or disorder that comprises a molecule or a pharmaceutical composition that induces an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion.

Abstract: Disclosed herein are molecules and pharmaceutical compositions that induce an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion. Also described herein include methods for treating a disease or disorder that comprises a molecule or a pharmaceutical composition that induces an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion.

Abstract: Disclosed herein are molecules and pharmaceutical compositions that induce an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion. Also described herein include methods for treating a disease or disorder that comprises a molecule or a pharmaceutical composition that induces an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion.

Abstract: Apparatus, systems, and methods may operate to receive radiated energy as scattered energy after the radiated energy interacts with a geologic formation, wherein the scattered energy is received at a sub-surface multi-channel sensor array that operates to transform the scattered energy into received signals, and wherein the radiated energy is provided by a sub-surface source of elastic energy; and to identify discontinuous features in the geologic formation by interferometric comparison of the received signals as elastic signals and/or electromagnetic signals among some sensors in the sensor array, or by time-reversal propagation of the received signals as elastic and/or electromagnetic signals in a numeric model of a volume of the geologic formation. Additional apparatus, systems, and methods are disclosed.

Abstract: Systems and methods for the conversion of stacked, or preferably, time migrated 3D seismic data and associated seismic attributes from a time domain to a depth domain.

Abstract: First seismic data is collected from a plurality of points on a reflecting feature in the formation by emitting a first seismic signal from a first array of source locations in a deviated portion of a first borehole drilled through a formation and receiving first reflections of the first seismic signal from the reflecting feature by a first array of receiver locations in a deviated portion of a second borehole drilled through the formation. Second seismic data is collected from the plurality of points on the reflecting feature in the formation by emitting a second seismic signal from a second array of source locations in the deviated portion of the first borehole, the second array of source locations being different from the first array of source locations, and receiving second reflections of the second seismic signal from the plurality of points on the reflecting feature by a second array of receiver locations in the deviated portion of the second borehole.

Abstract: Apparatus, systems, and methods may operate to receive radiated energy as scattered energy after the radiated energy interacts with a geologic formation, wherein the scattered energy is received at a sub-surface multi-channel sensor array that operates to transform the scattered energy into received signals, and wherein the radiated energy is provided by a sub-surface source of elastic energy; and to identify discontinuous features in the geologic formation by interferometric comparison of the received signals as elastic signals and/or electromagnetic signals among some sensors in the sensor array, or by time-reversal propagation of the received signals as elastic and/or electromagnetic signals in a numeric model of a volume of the geologic formation. Additional apparatus, systems, and methods are disclosed.

Abstract: A method for analyzing seismic data from a formation. The method may first receive two-dimensional (2-D) seismic data of a formation comprising a number of individual seismic lines acquired over an exploration area and having a large interline spacing. The 2-D seismic data may then be preprocessed to enhance diffracted energy. For each respective hypothetical diffractor location, the method may then search for coherent diffraction arrivals on nearby 2-D seismic lines consistent with the respective hypothetical diffractor location. The method may then store information regarding identified diffractor locations. The method may then create a map based on the identified diffractor locations, wherein the map illustrates areas of high diffraction. The map may then be displayed on a display, wherein the map is useable to assess the formation.

Abstract: A method for analyzing seismic data from a formation. The method may first receive two-dimensional (2-D) seismic data of a formation comprising a number of individual seismic lines acquired over an exploration area and having a large interline spacing. The 2-D seismic data may then be preprocessed to enhance diffracted energy. For each respective hypothetical diffractor location, the method may then search for coherent diffraction arrivals on nearby 2-D seismic lines consistent with the respective hypothetical diffractor location. The method may then store information regarding identified diffractor locations. The method may then create a map based on the identified diffractor locations, wherein the map illustrates areas of high diffraction. The map may then be displayed on a display, wherein the map is useable to assess the formation.

Abstract: The present invention provides antisense compounds and methods for modulating the expression of target genes expressed in the kidney. In particular, this invention provides antisense oligonucleotide compounds optimized for targeting nucleic acid molecules expressed in the kidney. Such compounds are shown herein to efficiently modulate the expression of target genes PTEN, SGLT2 and connective tissue growth factor (CTGF) in the kidney.

Abstract: Pharmaceutical compositions comprising sterically stabilized liposomes containing antisense oligonucleotides are provided for the modulation of expression of the human ras gene in both the normal (wildtype) and activated (mutant) forms.

Abstract: The compound 9-cis-retinoic acid, its pharmaceutically acceptable salts or its pharmaceutically acceptable esters can be used in the treatment of precancerous or premalignant epithelial lesions as well as in the treatment of malignant tumors of an epithelial nature.

Abstract: A water-soluble effervescent, layered denture cleanser tablet containing one or more enzymes in one layer and one or more active oxygen compounds in the other layer and in which the enzyme layer is faster dissolving than the active oxygen layer and is substantially completely dissolved before the dissolution of the active oxygen layer reaches a level which would inactivate the enzyme.